CoChat
Sign Up
Cited by 85Thyroid Cancer Diagnosis and TreatmentThyroid and Parathyroid SurgeryThyroid Disorders and Treatments

Multikinase inhibitors in the treatment of thyroid cancer: specific role of lenvatinib

Open access
Capdevila, Jaume, Stjepanovic, Neda·2014·Biologics: Targets and Therapy
DOI 10.2147/btt.s39381PMC PMC3990290
Open this paper in CoChat — free account

Abstract

Thyroid cancers are the most frequent neoplasms of the endocrine system and in the initial stages their prognosis is excellent. However, few therapeutic options are available for advanced or metastatic disease. In the last decade, a better understanding of the molecular events involved in the tumorigenesis of thyroid cancers has led to development of new targeted agents for the management of advanced and refractory disease. Multikinase inhibitors that are able to block pathways involved in the proliferation, invasion, and neoangiogenesis of thyroid cancer have been the most widely studied. After an international effort to identify and recruit sufficient patients, four placebo-controlled studies of multikinase inhibitors have been completed. These trials have led to the approval of the first agents with activity in advanced medullary thyroid cancers, which will probably change the landscape of treatment for iodine-refractory differentiated thyroid cancer in the near future. The purpose of this paper is to review the development of targeted agents for thyroid malignancy, with a special focus on lenvatinib, a multikinase inhibitor.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/btt.s39381

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Lenvatinib is an oral tyrosine kinase inhibitor of VEGFRs, FGFRs, PDGFRα, KIT, and RET.

    “Lenvatinib is an oral TKI of VEGFRs, FGFRs, PDGFRα, KIT, and RET.”

    From Lenvatinib Plus Ifosfamide and Etoposide in Children and Young Adults With Relapsed Osteosarcoma (2024) · cites this paper as [21]

    The Lenvatinib section describes lenvatinib as an oral multikinase inhibitor targeting VEGFR-1–3, FGFR-1–4, RET, and c-KIT. It specifies PDGFRβ, however, not the PDGFRα named in the citing sentence. (LLM, conf=0.91)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 50

  1. [1]Pellegriti G Frasca F Regalbuto C Squatrito S Vigneri R Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors J Cancer Epidemiol 2013 2013 965212 23737785 PMC3664492
  2. [2]Chen A Jemal A Ward EM Increasing incidence of differentiated thyroid cancer in the United States,1988–2005 Cancer 2009 115 16 3801 3807 19598221
  3. [6]Eustatia-Rutten CF Corssmit EP Biermasz NR Pereira AM Romijn JA Smit JW Survival and death causes in differentiated thyroid carcinoma J Clin Endocrinol Metab 2006 91 1 313 319 16263822
  4. [7]Durante C Haddy N Baudin E Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy J Clin Endocrinol Metab 2006 91 8 2892 2899 16684830
  5. [8]Sherman SI Cytotoxic chemotherapy for differentiated thyroid carcinoma Clin Oncol (R Coll Radiol) 2010 22 6 464 468 20452757
  6. [9]Wells SA Jr Robinson BG Gagel RF Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind Phase III trial J Clin Oncol 2012 30 2 134 141 22025146 PMC3675689
  7. [10]Elisei R Schlumberger MJ Müller SP Cabozantinib in progressive medullary thyroid cancer J Clin Oncol 2013 31 29 3639 3646 24002501 PMC4164813
  8. [11]Pawson T Regulation and targets of receptor tyrosine kinases Eur J Cancer 2002 38 Suppl 5 S3 S10 12528767
  9. [12]Nikiforova MN Nikiforov YE Molecular genetics of thyroid cancer: implications for diagnosis, treatment and prognosis Expert Rev Mol Diagn 2008 8 1 83 95 18088233
  10. [13]Ricarte-Filho JC Ryder M Chitale DA Mutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1 Cancer Res 2009 69 11 4885 4893 19487299 PMC2690720
  11. [14]Krause DS Van Etten RA Tyrosine kinases as targets for cancer therapy N Engl J Med 2005 353 2 172 187 16014887
  12. [15]Antonelli A Fallahi P Ferrari SM Dedifferentiated thyroid cancer: a therapeutic challenge Biomed Pharmacother 2008 62 8 559 563 18725177
  13. [16]Nikiforov YE Thyroid carcinoma: molecular pathways and therapeutic targets Mod Pathol 2008 21 Suppl 2 S37 S43 18437172 PMC2673022
  14. [17]Kroll TG Sarraf P Pecciarini L PAX8-PPARgamma1 fusion oncogene in human thyroid carcinoma [corrected] Science 2000 289 5483 1357 1360 10958784
  15. [18]Hou P Liu D Xing M Functional characterization of the T1799-1801del and A1799-1816ins BRAF mutations in papillary thyroid cancer Cell Cycle 2007 6 3 377 379 17297294
  16. [19]Saji M Ringel MD The PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumors Mol Cell Endocrinol 2010 321 1 20 28 19897009 PMC2849843
  17. [20]Mulligan LM Kwok JB Healey CS Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A Nature 1993 363 6428 458 460 8099202
  18. [21]Learoyd DL Messina M Zedenius J Robinson BG Molecular genetics of thyroid tumors and surgical decision-making World J Surg 2000 24 8 923 933 10865036
  19. [22]Holbro T Civenni G Hynes NE The ErbB receptors and their role in cancer progression Exp Cell Res 2003 284 1 99 110 12648469
  20. [23]Rodríguez-Antona C Pallares J Montero-Conde C Overexpression and activation of EGFR and VEGFR2 in medullary thyroid carcinomas is related to metastasis Endocr Relat Cancer 2010 17 1 7 16 19776290
  21. [24]Bottaro DP Rubin JS Faletto DL Identification of the hepatocyte growth factor receptor as the c-met proto-oncogene product Science 1991 251 4995 802 804 1846706
  22. [25]Klein M Picard E Vignaud JM Vascular endothelial growth factor gene and protein: strong expression in thyroiditis and thyroid carcinoma J Endocrinol 1999 161 1 41 49 10194527
  23. [26]Bunone G Vigneri P Mariani L Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features Am J Pathol 1999 155 6 1967 1976 10595926 PMC1866941
  24. [27]Kerbel RS Tumor angiogenesis N Engl J Med 2008 358 19 2039 2049 18463380 PMC4542009
  25. [28]Eggo MC Hopkins JM Franklyn JA Johnson GD Sanders DS Sheppard MC Expression of fibroblast growth factors in thyroid cancer J Clin Endocrinol Metab 1995 80 3 1006 1011 7533768
  26. [29]Wesche J Haglund K Haugsten EM Fibroblast growth factors and their receptors in cancer Biochem J 2011 437 2 199 213 21711248
  27. [30]Haugsten EM Wiedlocha A Olsnes S Wesche J Roles of fibroblast growth factor receptors in carcinogenesis Mol Cancer Res 2010 8 11 1439 1452 21047773
  28. [31]St Bernard R Zheng L Liu W Winer D Asa SL Ezzat S Fibroblast growth factor receptors as molecular targets in thyroid carcinoma Endocrinology 2005 146 3 1145 1153 15564323
  29. [33]Dieci MV Arnedos M Andre F Soria JC Fibroblast growth factor receptor inhibitors as a cancer treatment: from a biologic rationale to medical perspectives Cancer Discov 2013 3 3 264 279 23418312
  30. [34]Polverino A Coxon A Starnes C AMG 706, an oral, multikinase inhibitor that selectively targets vascular endothelial growth factor, platelet-derived growth factor, and kit receptors, potently inhibits angiogenesis and induces regression in tumor xenografts Cancer Res 2006 66 17 8715 8721 16951187
  31. [35]Sherman SI Wirth LJ Droz JP Motesanib diphosphate in progressive differentiated thyroid cancer N Engl J Med 2008 359 1 31 42 18596272
  32. [37]Cohen EE Rosen LS Vokes EE Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a Phase II study J Clin Oncol 2008 26 29 4708 4713 18541897 PMC4859206
  33. [38]Locati L Licitra L Agate I Phase 2 trial of axitinib for advanced thyroid cancer: preliminary activity results Presented at the Fifth European Conference on Head and Neck Oncology Poznan, Poland April 18–21, 2012
  34. [39]Kloos RT Ringel MD Knopp MV Phase II trial of sorafenib in metastatic thyroid cancer J Clin Oncol 2009 27 10 1675 1684 19255327 PMC2668972
  35. [40]Gupta-Abramson V Troxel AB Nellore A Phase II trial of sorafenib in advanced thyroid cancer J Clin Oncol 2008 26 29 4714 4719 18541894 PMC2653134
  36. [41]Hoftijzer H Heemstra KA Morreau H Beneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinoma Eur J Endocrinol 2009 161 6 923 931 19773371
  37. [42]Ahmed M Barbachano Y Riddell A Analysis of the efficacy and toxicity of sorafenib in thyroid cancer: a Phase II study in a UK based population Eur J Endocrinol 2011 165 2 315 322 21566072
  38. [44]Lam ET Ringel MD Kloos RT Phase II clinical trial of sorafenib in metastatic medullary thyroid cancer J Clin Oncol 2010 28 14 2323 2330 20368568 PMC2881718
  39. [45]Capdevila J Iglesias L Halperin I Sorafenib in metastatic thyroid cancer Endocr Relat Cancer 2012 19 2 209 216 22285864
  40. [48]Carr LL Mankoff DA Goulart BH Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation Clin Cancer Res 2010 16 21 5260 5268 20847059 PMC3063514
  41. [50]Bible KC Suman VJ Molina JR Efficacy of pazopanib in progressive, radioiodine-refractory, metastatic differentiated thyroid cancers: results of a Phase 2 consortium study Lancet Oncol 2010 11 10 962 972 20851682 PMC3107731
  42. [51]Bible KC Suman VJ Menefee ME A multiinstitutional Phase 2 trial of pazopanib monotherapy in advanced anaplastic thyroid cancer J Clin Endocrinol Metab 2012 97 9 3179 3184 22774206 PMC3431569
  43. [52]Wells SA Jr Gosnell JE Gagel RF Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer J Clin Oncol 2010 28 5 767 772 20065189 PMC2834392
  44. [53]Robinson BG Paz-Ares L Krebs A Vasselli J Haddad R Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer J Clin Endocrinol Metab 2010 95 6 2664 2671 20371662 PMC2902067
  45. [54]Leboulleux S Bastholt L Krause T Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, Phase 2 trial Lancet Oncol 2012 13 9 897 905 22898678
  46. [55]Kurzrock R Sherman SI Ball DW Activity of XL184 (cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer J Clin Oncol 2011 29 19 2660 2666 21606412 PMC3646303
  47. [56]Matsui J Funahashi Y Uenaka T Watanabe T Tsuruoka A Asada M Multi-kinase inhibitor E7080 suppresses lymph node and lung metastases of human mammary breast tumor MDA-MB-231 via inhibition of vascular endothelial growth factor-receptor (VEGF-R) 2 and VEGF-R3 kinase Clin Cancer Res 2008 14 17 5459 5465 18765537
  48. [57]Grande E Diez JJ Zafon C Capdevila J Thyroid cancer: molecular aspects and new therapeutic strategies J Thyroid Res 2012 2012 847108 22848860 PMC3403487
  49. [58]Boss DS Glen H Beijnen JH A Phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours Br J Cancer 2012 106 10 1598 1604 22516948 PMC3349182
  50. [61]Schlumberger M Jarzab B Cabanillas ME A Phase II trial of the multitargeted kinase inhibitor lenvatinib (E7080) in advanced medullary thyroid cancer (MTC) J Clin Oncol 2012 30 Suppl Abstr 5591 26311725

Cited by

Sorted by citations

Authors
Capdevila, J., & Stjepanovic, N.
Affiliations
Vall d'Hebron Hospital Universitari (ES)
Corresponding author
Capdevila, Jaume
ORCID
Venue
Biologics: Targets and Therapy
Publisher
Informa UK Limited
Published
2014-04
Volume
8
Pages
129
ISSN
1177-5475 (ISSN-L)
DOI
10.2147/btt.s39381
PMC
PMC3990290
OpenAlex
W2068644298
Cited by
85
References
2
Citations by year
2025: 3 · 2024: 4 · 2023: 12 · 2022: 7 · 2021: 8 · 2020: 7 · 2019: 10 · 2018: 7 · 2017: 6 · 2016: 9 · 2015: 7 · 2014: 5
FWCI
7.24
Type
journal article
Language
en
Open access
Licence
Locations
  • Biologics (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • Dove Medical Press (Taylor and Francis Group) (submittedVersion, cc-by-nc)
Topics
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Cancer Diagnosis and Treatment
  • Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
Keywords
multikinase inhibitor, lenvatinib, thyroid cancer, medullary thyroid carcinoma, differentiated thyroid cancer, radioiodine-refractory thyroid cancer, targeted therapy, angiogenesis inhibition, drug approval

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review